ArticleAntimicrobial agents and chemotherapy2006
Mycobacterium leprae is naturally resistant to PA-824.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects.Antimicrobial agents and chemotherapy · 2009Trial
- Uncovering interactions between mycobacterial respiratory complexes to target drug-resistantFrontiers in cellular and infection microbiology · 2022Review
- Whole Genome Sequencing for the Analysis of Drug Resistant Strains ofAntibiotics (Basel, Switzerland) · 2020Review
- Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase fromInfection and drug resistance · 2020Article
- Targeting the Mycobacterium ulcerans cytochrome bcNature communications · 2018Article
- Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824).Scientific reports · 2018Article
- Nitazoxanide is active against Mycobacterium leprae.PloS one · 2017Article
- Physiology, Biochemistry, and Applications of F420- and Fo-Dependent Redox Reactions.Microbiology and molecular biology reviews : MMBR · 2016Review
- Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy.Risk management and healthcare policy · 2016Review
- Magnitude of Neglected Tropical Diseases in Indonesia at Postmillennium Development Goals Era.Journal of tropical medicine · 2016Review
- glpx Gene in Mycobacterium tuberculosis Is Required for In Vitro Gluconeogenic Growth and In Vivo Survival.PloS one · 2015Article
- Advances in the development of new tuberculosis drugs and treatment regimens.Nature reviews. Drug discovery · 2013Review
- In vitro activities of the new antitubercular agents PA-824 and BTZ043 against Nocardia brasiliensis.Antimicrobial agents and chemotherapy · 2012Article
- Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824.Structure (London, England : 1993) · 2012Article
- An enlarged, adaptable active site in CYP164 family P450 enzymes, the sole P450 in Mycobacterium leprae.Antimicrobial agents and chemotherapy · 2012Article
- Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824.Antimicrobial agents and chemotherapy · 2011Article
- Advances and hurdles on the way toward a leprosy vaccine.Human vaccines · 2011Review
- New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Antimicrobial agents and chemotherapy · 2009Review
- A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents.The Journal of antimicrobial chemotherapy · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Leprosy responds very slowly to the current multidrug therapy, and hence there is a need for novel drugs with potent bactericidal activity. PA-824 is a 4-nitroimidazo-oxazine that is currently undergoing phase I clinical trials for the treatment of tuberculosis. The activity of PA-824 against Mycobacterium leprae was tested and compared with that of rifampin in axenic cultures, macrophages, and two different animal models. Our results conclusively demonstrate that PA-824 has no effect on the viability of M. leprae in all three models, consistent with the lack of the nitroimidazo-oxazine-specific nitroreductase, encoded by Rv3547 in the M. leprae genome, which is essential for activation of this molecule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.